Like you know something isn’t right with your health, but the doctor either dismissed your concerns or prescribed a ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...

Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...

1 “Atopic dermatitis often affects multiple regions of the body but can be exceptionally burdensome and difficult to treat in the head and neck,” said Kreesten Meldgaard Madsen, Chief Developm ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Atopic dermatitis, especially when affecting visible areas like the head and neck, can significantly impact patients' quality of life. Studies such as UP-TAINED and AD-VISE have indicated that a ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

The analysis evaluated the efficacy of upadacitinib (15 mg or 30 mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by the severity of disease in the head and neck region at ...

The analysis evaluated the efficacy of upadacitinib (15 mg or 30 mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by the severity of disease in the head and neck region at ...

efficacy of RINVOQ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results in skin clearance, itch resolution ...